More nasal spray flu vaccine coming - officials

Key points
- Another 1 million doses of a nasal spray influenza vaccine will be available in the United States this year, Bush administration officials said on Thursday as they sought to calm concerns about a flu shot shortage.
- The spray vaccine, called FluMist and made by Gaithersburg, Maryland-based MedImmune Inc., is approved only for healthy people aged 5 to 49.
- The United States will have enough vaccine and antiviral medicines "to cope with this year's flu season, even if it turns out to be a severe season," Health and Human Services Secretary Tommy Thompson told reporters.
- Officials also are negotiating with France and Canada and talking to some European companies in hopes of obtaining any surplus vaccine, Acting Food and Drug Administration Commissioner Lester Crawford said.
Another 1 million doses of a nasal spray influenza vaccine will be available in the United States this year, Bush administration officials said on Thursday as they sought to calm concerns about a flu shot shortage.
The spray vaccine, called FluMist and made by Gaithersburg, Maryland-based MedImmune Inc., is approved only for healthy people aged 5 to 49. It is not intended for the elderly, very young children and others at high risk of serious flu complications.
The United States will have enough vaccine and antiviral medicines "to cope with this year's flu season, even if it turns out to be a severe season," Health and Human Services Secretary Tommy Thompson told reporters.
Officials also are negotiating with France and Canada and talking to some European companies in hopes of obtaining any surplus vaccine, Acting Food and Drug Administration Commissioner Lester Crawford said. Up to 5 million more doses might become available, Crawford said.
President Bush, speaking at a campaign stop in Pennsylvania, acknowledged growing public concern about the shortage and sought to offer reassurance and advice.
"If you're feeling healthy like I'm feeling healthy these days, don't get in line for the flu shot," Bush said, alluding to the long lines that have formed in parts of the country.
Shortages of the flu prevention shots have become a campaign issue for Bush as his Democratic challenger, Sen. John Kerry, has accused him of not having done enough to ensure sufficient stocks.
A total of 3 million FluMist doses will be available in the U.S. market for the current flu season, along with 58 million flu shots made by France-based Aventis-Pasteur.
U.S. officials had hoped to have 100 million flu vaccine doses available this year, but maker Chiron Corp. lost its license to make the inoculation on Oct. 5. Emeryville, California-based Chiron had been expected to supply the U.S. market with 48 million doses.
Influenza kills about 36,000 Americans in an average year and lands about 200,000 in the hospital.
Thompson urged seniors not to stand in long lines waiting for the vaccine, as that could threaten their health.
Millions of flu vaccine doses have yet to be distributed, he stressed. Aventis-Pasteur is shipping an average of up to 3 million doses each week to health-care providers.
"Just because your doctor does not have the vaccine today does not mean he or she ... (will) not get it" in the coming weeks, Thompson said.
Democratic vice presidential candidate John Edwards charged Thompson with spending too much time campaigning for Bush. "It's a problem when the secretary of HHS, instead of dealing with the flu vaccine crisis, is out campaigning in battleground states," Edwards said.
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Infections, HIV & STIs →
NewsResearchers find potential map to more effective HIV vaccine
By tracking the very earliest days of one person's robust immune response to HIV, researchers have charted a new route for developing a long-sought vaccine that could boost the body's ability to neutralize the virus.…
4 April 2013
NewsStudy offers new way to discover HIV vaccine targets
Decades of research and three large-scale clinical trials have so far failed to yield an effective HIV vaccine, in large part because the virus evolves so rapidly that it can evade any vaccine-induced immune response.…
22 March 2013
NewsFlu vaccine less helpful for elderly than usual this year
It turns out this year's flu shot is doing a startlingly dismal job of protecting older people, the most vulnerable age group. The vaccine is proving only 9 percent effective in those 65 and older against the harsh…
25 February 2013




